Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up study

Abstract

Ranibizumab was an effective treatment for stabilising and improving vision with a low number of injections in 92.5% of patients with myopic CNV in a long-term follow-up.

Therapeutic effect of intravitreal injections of ranibizumab for the treatment of macular choroidal neovascularization caused by pathological myopia

“…Comparative observations of indocyanine-green angiography (ICGA) and FFA have shown that the two techniques have a discovery rate of lacquer crack-like lesions of 89 and 38%, respectively, indicating that ICGA can detect these lesions more effectively than can FFA (8). In the present study, lacquer cracks were detected in 40 out of 61 eyes (65.6%) with pathological myopia-induced macular CNV.…”

“…Figurska and Stankiewicz (19) reported an Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity improvement of two lines in a 55-year-old patient who received two intravitreal injections of ranibizumab; furthermore, the ETDRS visual acuity was improved by three lines in another 25-year-old patient who received three intravitreal ranibizumab injections. A similar study (8) reported that the average number of intravitreal ranibizumab injections required to treat pathological myopia-induced macular CNV was 2.2, and the average BCVAs were 0.01 (prior to the treatment) and 0.30 (subsequent to the treatment). In the present study, the average number of injections was 1.97, and the average BCVAs were 0.02±0.01 and 0.30±0.03 prior to and subsequent to treatment, respectively.…”

“…The reason for this small improvement is unclear and further research is required to determine why certain eyes may not respond to this injection. Previous studies have assessed the number of treatments required and the post-treatment visual outcomes following intravitreal ranibizumab injection (8,19). Figurska and Stankiewicz (19) reported an Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity improvement of two lines in a 55-year-old patient who received two intravitreal injections of ranibizumab; furthermore, the ETDRS visual acuity was improved by three lines in another 25-year-old patient who received three intravitreal ranibizumab injections.…”

“…Although the drug bevacizumab has not yet obtained clinical recognition, it has received some distinction in the treatment of pathological myopia-induced CNV (7). By contrast, ranibizumab (Lucentis ® ; Novartis Pharma AG, Basel, Switzerland), which has been clinically registered for the treatment of AMD, has been described as a treatment for pathological myopia-induced CNV in only a few reports (8)(9)(10).…”

Comparison of foveal-sparing with foveal-involving photodynamic therapy for myopic choroidal neovascularization

“…6,[8][9][10][11][12] The mean final VA in patients treated with anti-VEGF drugs reported in the literature ranges from 0.23 to 0.55 (Table 2). [6][7][8][9][10][11][12][31][32][33][34][35][36] More importantly, in studies which have compared anti-VEGF with PDT treatment for myopic CNV, patients treated with anti-VEGF generally achieved better visual outcomes compared with the group treated with PDT. 7,24,25 It is important to note, however, that in these studies, patients…”